As the weight came off, she felt lighter, more energetic, and more in tune with herself than she had in years
Eli Lilly, the maker of Mounjaro and Zepbound, said Thursday that the company's new orforglipron pill can offer up to an average of 27.3 pounds of weight loss, according to results from the first of two of its Phase 3 trials that included more than 3,100 overweight or obese adults
5.1.1 Pharmacotherapies with dual benefits GLP-1R agonists (GLP-1RAs) like semaglutide, liraglutide and SGLT2 inhibitors (SGLT2i) like empagliflozin, dapagliflozin, originally developed for T2DM, demonstrate pleiotropic benefits for both muscle and vasculature (137139)
After discussing potential treatment options, the patient agreed to pharmacological treatment